The prognosis of patients with malignant gliomas remains dismal. To treat patients with this deadly disease more effectively, we must identify the common aberrations in the signaling pathways that are responsible for the invasive and drug-resistant nature of malignant gliomas. Merlin is a member of the Band 4.1 superfamily proteins. Mutations and deletions of merlin cause the neurofibromatosis type 2 (NF2), which is characterized by development of schwannomas, meningiomas, and ependymomas. Mutations of the NF2 gene have also been found in other cancers, suggesting that merlin is important for a variety of cancers. We have demonstrated recently that merlin is absent or down regulated in high-grade gliomas and that increased expression of merlin dramatically inhibits subcutaneous and intracranial growth of human gliomas in vivo. In addition, we demonstrated that increased expression of merlin is linked to activation the Lats2 tumor suppressorsignaling pathway and inhibition of Wnt and c-Met oncogenic signaling pathways. We showed that Lats2, canonical Wnt, RhoA, and c-Met signaling pathways play important roles in glioma growth in vivo. Based on these results, we hypothesize that merlin is a key negative regulator of the growth and progression of human gliomas and that the essential downstream signaling pathways of merlin are the Lats2, Wnt, and c-Met signaling pathways in human glioma cells. We further hypothesize that merlin can sensitize the response of glioma cells to the chemotherapeutic drugs in vivo.
Two specific aims are proposed to test these hypotheses.
Aim 1 is to determine the essential downstream effectors of merlin in malignant human gliomas by establishing that merlin activates Lats2 signaling and inhibits Wnt and c-Met signaling pathways.
Aim 2 is to provide a novel therapeutic strategy for human gliomas by establishing that merlin sensitizes the response of glioma cells to chemotherapeutic drugs in vivo. Results from the proposed studies will advance our understanding in the essential role of merlin signaling in glioma progression and will establish that the essential downstream signaling pathways of merlin are prime targets for anti-glioma therapy and provide strong basis to conduct future preclinical studies to test the existing pharmacological agents that inhibit these essential downstream signaling pathways of merlin. Therefore, this proposal has high biological and clinical relevance

Public Health Relevance

In order to treat malignant glioma more effectively, we must better understand its molecular pathogenesis and identify the common aberrations in the signaling pathways that are responsible for the invasive and drug-resistant nature of malignant gliomas. Our recent results have demonstrated for the first time that lost or weakened tumor suppressor signaling of merlin is essential for glioma growth and progression and that increased expression of merlin alters the activities of several important downstream signaling pathways. This proposal is to establish the downstream effectors of merlin and identify the novel combination therapeutic strategy by determining whether merlin can sensitize the response of glioma cells to the chemotherapeutic drugs in vivo and therefore, this proposal is of high biologic and therapeutic relevance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA135158-01A1
Application #
7672177
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Forry, Suzanne L
Project Start
2009-09-01
Project End
2011-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$349,048
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Xu, Yin; Wang, Kaiqiang; Yu, Qin (2016) FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases. Oncotarget 7:70080-70091
Gong, Yixuan; Scott, Evita; Lu, Rong et al. (2013) TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression. PLoS One 8:e77366
Brunckhorst, Melissa K; Lerner, Dimitry; Wang, Shaomeng et al. (2012) AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biol Ther 13:804-11
Murray, Lucas B; Lau, Ying-Ka Ingar; Yu, Qin (2012) Merlin is a negative regulator of human melanoma growth. PLoS One 7:e43295
Xu, Yin; Stamenkovic, Ivan; Yu, Qin (2010) CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res 70:2455-64
Stamenkovic, Ivan; Yu, Qin (2010) Merlin, a ""magic"" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci 11:471-84
Lau, Ying-Ka Ingar; Murray, Lucas B; Houshmandi, Sean S et al. (2008) Merlin is a potent inhibitor of glioma growth. Cancer Res 68:5733-42